12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Qnasl beclomethasone dipropionate nasal aerosol: Additional Phase III data

Additional data from a double-blind, U.S. Phase III trial in 715 patients aged 6-11 showed that once-daily 80 and 160 µg Qnasl significantly improved patient-reported AM and PM instantaneous TNSS vs. placebo (p<0.01). Qnasl also significantly improved physician-assessed nasal symptom scores (PNSS) by 0.096 points (p<0.001)...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >